en pharmacology pharmacology Original Article Original Article <p><span style="color:#0000FF;"><strong><em><span style="font-family:times new roman;">Background:</span></em></strong></span> <span style="font-family:times new roman;">Azithromycin (AZM) is used in periodontal infections. The present study compared gingival crevicular fluid concentration of azithromycin of two pharmaceutical companies through the HPLC method.</span></p> <p><span style="font-family:times new roman;"><span style="color:#0000FF;"><strong><em>Methods:</em></strong> </span>Two groups (n=15) of healthy volunteers participated in this study. The first group received an imported azithromycin (ImAZM) tablet (250 mg, PO) and the second group received an azithromycin tablet (250 mg PO) manufactured by an Iranian pharmaceutical company (IrAZM). Intrasulcular paper points (#30) were used in inter-proximal areas of molars and canines to collect gingival crevicular fluid samples at 6, 12, 36, 84 and 156 hours after drug administration.</span></p> <p><span style="font-family:times new roman;"><span style="color:#0000FF;"><strong><em>Results:</em></strong></span> The maximum concentration of AZM in gingival crevicular fluid was detected in each group 36 hour after administration. The concentration levels for the participants receiving ImAZM and IrAZM were 14.38&plusmn;5.75 and 12.64&plusmn;3.53 ng/mL, respectively. The pharmacokinetic (PK) modeling data showed half-life of AZM was 107.47 hr & 91.42 hr while the clearance was 113.02 hr &119.0 hr for the group receiving ImAZM and IrAZM, respectively. No significant differences were observed in other PK parameters, areas under the concentration time curves for the groups were almost identical.</span></p> <p><span style="font-family:times new roman;"><span style="color:#0000FF;"><strong><em>Conclusion: </em></strong></span>According to the results, there were no significant differences between the PK parameters of ImAZM and IrAZM products. It may be concluded that different doses of AZM have relatively similar PK parameters among the healthy participants.</span></p> Azithromycin, Pharmacokinetics, HPLC, Gingival crevicular fluid 260 266 http://caspjim.com/browse.php?a_code=A-10-108-1&slc_lang=en&sid=1 Mahmoud Khosravi Samani samani_dr@yahoo.com 10031947532846009554 10031947532846009554 No Department of Periodontology, Babol University of medical sciences, Babol, Iran Khashayar Dehshiri drdehshiry@yahoo.com 10031947532846009555 10031947532846009555 No Department of Periodontology, Babol University of medical sciences, Babol, Iran Sohrab Kazemi kazemi.msm@gmail.com 10031947532846009556 10031947532846009556 No 2. Neurosciences Research Center, Department of Pharmacology, Babol University of medical sciences, Babol, Iran Mohamadreza Shiran mohamadreza.shiran@yahoo.com 10031947532846009557 10031947532846009557 No 3. Department of Pharmacology, Mazandaran University of medical science, Sari, Iran Ali Akbar Moghadamnia moghadamnia@gmail.com 10031947532846009558 10031947532846009558 Yes 2. Neurosciences Research Center, Department of Pharmacology, Babol University of medical sciences, Babol, Iran